SecBot SecBot

IMRX

Immuneering Corp
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001790340 Biotech & Drug Discovery
$3.86 +0.15 (+4.04%)
Oct 27 4:00 PM ET · prev $3.71
Market cap
$246.5M
Micro cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$15.50
+302% · range $12.00–30.00
Next earnings
Nov 5
in 9 days · EPS est. −$0.31
1 year
−38.7%
from $6.30 · Oct 27
30 days
−7.2%
from $4.16
52-week range
$3.42–8.33
−54% from high · low Oct 14
Avg volume 20D
701.0K
Oct 8 spike 1.92M
Short interest
🔒 Subscribers only
Insider net
+$36.0K
2 buyers · 0 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH Immuneering presented exploratory Phase 2a data at AACR Pancreatic Cancer 2026 showing that pancreatic…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $36.0K at an average $4.27. No open-market sales. Price is 10% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 17 added (1 new), 8 trimmed or exited. Largest new: Vanguard Capital Management $11.4M.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.306 → −$0.306 over 90 days. 1 up, 2 down in 30 days.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$11.4M
in new stakes
FundMoveSharesValue
BlackRock, Inc.DOUBLED4,374,020$21.8M
VANGUARD CAPITAL MANAGEMENT LLCNEW2,286,434$11.4M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,370,750$6.8M
STATE STREET CORPDOUBLED1,001,995$5.0M
MARSHALL WACE, LLPTRIM731,897$3.7M
Connor, Clark & Lunn Investment Management Ltd.ADD601,255$3.0M
NORTHERN TRUST CORPDOUBLED436,992$2.2M
MILLENNIUM MANAGEMENT LLCTRIM330,402$1.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy8Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +302%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 6, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Jul 20, 2026Needham
MAINTAIN
MAINTAINBuy
Jul 8, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
May 19, 2026Chardan Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$36.0K
bought · 2 insiders
$0
sold · 0 insiders
−9.5%
vs their $4.27 cost
DateInsiderTypeValue
Jul 16, 2026
Gengos Andrew
Chief Financial Officer
AWARD650,000 sh
Jun 23, 2026
Zeskind Benjamin J.
PRESIDENT AND CEO
BUY$10.9K
Jun 15, 2026
Hall Brett Matthew
CHIEF SCIENTIFIC OFFICER
BUY$25.0K
Jun 11, 2026
Feinberg Peter
Director
AWARD33,350 sh
Jun 11, 2026
KEATING LAURIE
Director
AWARD33,350 sh
Jun 11, 2026
CARPENTER ROBERT J
Director
AWARD33,350 sh
Jun 11, 2026
HAUSMAN DIANA
Director
AWARD33,350 sh
Jun 11, 2026
Schall Thomas J.
Director
AWARD33,350 sh

Earnings setup

Estimates
Nov 5
reports in 9 days
−$0.31
EPS estimate, this quarter
0%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.31-$0.37–-$0.27+0.0%$0.00
Next Q-$0.34-$0.45–-$0.28+0.0%$0.00
Current FY-$1.12-$1.30–-$1.03+0.0%$0.00
Next FY-$1.26-$1.65–-$0.29+0.0%$19.5M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Press
Immuneering presented a trial-in-progress poster at ESMO 2026 for its pivotal Phase 3 trial (MAPKeeper 301) evaluating…
Impact 3/10
Oct 26, 2026 FDA
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress
Oct 2, 2026 Press
Immuneering announced a poster presentation at SITC 2026 showing that atebimetinib enhances PD-1 checkpoint blockade…
Impact 3/10
Aug 5, 2026 SEC
Immuneering reported Q2 2026 results with a net loss of $17.3M ($0.27/share), widening from $14.4M ($0.40/share) in Q2…
8-K — Impact 5/10
Aug 5, 2026 SEC
Immuneering reported Q2 2026 net loss of $17.3M ($0.27/share), wider than the $14.4M loss in Q2 2025, driven by…
PRESS-RELEASE — Impact 5/10
Jul 16, 2026 Insider
Gengos Andrew was granted 650,000 shares
Chief Financial Officer
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
4,374,020 shares ($21.8M)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — NEW
2,286,434 shares ($11.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
IMRX Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Oct 26, 2026
FDA
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Oct 20, 2026
Clinical Trial
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Phase 2 · ACTIVE_NOT_RECRUITING
Oct 2, 2026
FDA
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Sep 28, 2026
FDA
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark…
Sep 24, 2026
Press release
Immuneering to Present at the ESMO Congress 2026
Immuneering to Present at the ESMO Congress 2026

SecBot reports

6 filings · 6 press releases · 2 bullish · 0 bearish · 4 neutral
All IMRX filing & press-release reports (12)